Investor Presentaiton

Continuously Strong Support from Globally Renowned Investors Total fundraising since inception: US$ 2.6bn+ The largest IPO fund raise at the time for pre-revenue biopharmaceutical company Strong support from globally renowned investors from pre- IPO to post-IPO Pre-IPO Fund Raising Total follow-on offering: ~US$ 1.6bn The first and only HK biotech 18A with successful 4 rounds follow-on Industry Leader Receives More Attention and Focus by Capital Markets US$ 562m Lilly Asia Ventures Fidelity 礼来亚洲基金 TEMASEK HOLDINGS CAPITAL GROUP SDIC 国投创新 HILLHOUSE CAPITAL GIC ROCK SPRINGS IPO Total Proceeds CORMORANT ASSET MANAGEMENT CAPITAL |理成 LEGEND 資産 CAPITAL Ally Bridge Group 君联资本 Greenwoods 景林 F Fidelity INTERNATIONAL WELLINGTON MANAGEMENT SEQUOIA UBS Global Asset Management LAKE BLEU CAPITAL Innovent Continued interests and confidence of global investors PRIME CAPITAL OppenheimerFunds BlackRockⓇ US$ 485m Track record in value delivering Capability to exceed market expectations Value Partners Invesco Investing through discipline Follow-on Offerings 13 中国平安 US$ 1.6bn 中国人寿 PING AN CHINA LIFE 清池资本 Confidential Copyright©2021 Innovent Biologics Removed "B" marker and was included in the Hang Seng Composite index and included in the Stock Connect 38 88

View entire presentation